Key result
Intentional permanent atrial pacing linked to ~78% fewer breakthrough cardiac events in high-risk LQTS.
Why the study?
Some patients with long QT syndrome experience breakthrough cardiac events despite maximal therapy, prompting evaluation of genotype-specific utilization and efficacy of intentional permanent atrial pacing.
Does intentional permanent atrial pacing reduce breakthrough cardiac events in high-risk patients with congenital long QT syndrome?
Cohort (n=52)
No
Does intentional permanent atrial pacing reduce breakthrough cardiac events in high-risk patients with congenital long QT syndrome?
Intentional permanent atrial pacing is a safe and efficacious adjunct therapy that significantly reduces breakthrough cardiac events and QTc in high-risk LQTS patients, particularly those with LQT2.
Answers are grounded in this paper and cite their sources.
May support atrial pacing in refractory high-risk LQTS; hypothesis-generating and leaves open randomized confirmation.
BACKGROUND: Unfortunately, some patients with long QT syndrome (LQTS) experience breakthrough cardiac events (BCEs) despite maximal therapy. Small studies have shown that refractory LQTS cases may benefit from intentional permanent atrial pacing (IPAP). As such, we sought to determine the genotype-specific utilization and efficacy of IPAP in a single-center LQTS registry. METHODS AND RESULTS: In this retrospective study, electronic medical records from 1065 patients diagnosed with LQTS were used to identify individuals that received IPAP. Pre- and post-IPAP heart rate, heart rate-corrected QT (QTc) values, annual BCE rate, and IPAP-related complications were compared between genotypes. BCEs were defined as LQTS-associated syncope/seizures, sustained ventricular arrhythmia (VA)-terminating ICD therapies, and sudden cardiac arrest/death. Overall, 52 out of 1065 LQTS patients received adjunctive IPAP therapy (77% female; median age 18.5 [interquartile range, 1-35.5] years; 73% with prior VA). Over an average IPAP follow-up of 121 ± 82 months, the average heart rate increased from 65.8 ± 20.4 bpm to 78.9 ± 17.1 bpm; (p < .01) and the average QTc decreased from 533.4 ± 66.6 to 488.3 ± 52.4 ms; (p < .01). The mean BCE rate dropped from 0.88 to 0.19 per patient-year (p = .01), driven by a marked decrease in the LQT2 cohort (1.01 BCE/year to 0.02 BCE/year; p = .003). No serious IPAP-related complications were observed. CONCLUSION: In high-risk LQTS patients, namely those with recalcitrant LQT2, IPAP appears to be a safe and efficacious adjunct therapy. The beneficial effects of IPAP may stem from attenuating the QTc and circumventing a pause-dependent trigger. Whether IPAP might obviate the need for an ICD in some instances warrants further study.
No takes yet. Share an insight, caveat, or question.
Kowlgi et al. (2021) conducted a cohort in long QT syndrome (LQTS) (n=52). Intentional permanent atrial pacing (IPAP) vs. Pre-IPAP baseline was evaluated on Annual breakthrough cardiac event (BCE) rate (p=0.01). Intentional permanent atrial pacing reduced the mean breakthrough cardiac event rate from 0.88 to 0.19 per patient-year (p=0.01) in high-risk patients with long QT syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: